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Background
Studies have shown that transmitted drug resistance
mutations involving major antiretroviral classes appear
to persist for months, even years, after infection. Efficacy
of antiretroviral treatment in recently infected indivi-
duals imply resistance testing prior to initialize treat-
ment. The prevalence of drug resistance mutations in
patients newly infected with HIV-1 is high throughout
the world and little is known about transmission of
resistant virus in non B subtypes. In Romania from 1992
to 2009, analysis of the relative incidence of different
HIV-1 circulating strains revealed a stable profile with
high prevalence of subtype - F, in both long term survi-
vors and recently infected adults.
Objectives
To study the prevalence of transmitted drug resistance
and asses the type of mutations fond in F subtype
recently diagnosed and naïve patients.
Materials and methods
Sequencing of the pol gene was carried out using Tru-
gene genotyping kits, (Bayer diagnostics) in plasma sam-
ples from 10 recently diagnosed adults, average age 28.9
±5.2 years, parenterally HIV infected. The nucleotide
sequences were submitted to the Stanford database, and
all strains were found to belong to the F subtype.
Results
All patients had clinical progression, median CD4 count
was 143.6cells/mmc (range 8-490); median HIV ARN was
380278.5copies/ml plasma (range38000-1020000) and they
need to initialize antiretroviral treatment. We found PI
major resistance mutations in 2 patients: the mutations
were V82S, V82 F, I84L; NRTI resistance mutations in 7
patients, the mutations were: M41L, A62P, D67G, F77L,
Q151R, K219P, M41V, T215N, K219Q, D67A, T69N,
K70R, T215I, K219N and NNRTI resistance mutations in
3 patients, the mutations were: L100S, K103N, F227L,
V179D, Y181S . All patients presented other mutations in
average number of 11.5±2 for protease and 26.7±19.8 for
reverse transcriptase. From the type 2 TAMs recognized
to confer NRTI drug resistance only K70R was found in 2
patients also K103N associated with primary NNRTI resis-
tance was found in one patient. The L89M polymorphism,
the most prevalent signature among treatment-naïve non-
subtype B isolates, was found in 7 patients.
Conclusions
Due to transmitted drug resistance only 3 of the tested
patients could have been treated with any kind of antire-
troviral therapy, the rest, 70%, have limited therapy
option. If genotyping is not performed prior choosing
an antiretroviral combination the chances of therapy
efficacy are low.
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